Atrial fibrillation on vitamin K-antagonists undergoing elective coronary artery stenting for stable effort angina -- Atrial fibrillation on NOAC (dabigatran) undergoing elective coronary artery stenting for stable effort angina -- Atrial fibrillation on vitamin K-antagonist undergoing urgent coronary stenting for non ST-elevation acute coronary syndrome -- Atrial fibrillation on NOAC (rivaroxaban) undergoing urgent coronary stenting for non ST-elevation acute coronary syndrome -- Atrial fibrillation on vitamin K-antagonist undergoing emergency primary coronary stenting for ST-elevation acute myocardial infarction -- Atrial fibrillation on NOAC (apixaban) undergoing emergency primary coronary stenting for ST-elevation acute myocardial infarction -- Atrial fibrillation early complicating acute coronary syndrome treated with coronary artery stenting -- New-onset atrial fibrillation in a stable patient with remote coronary artery stenting -- Urgent surgery early after coronary stenting in a patient with atrial fibrillation on triple therapy of warfarin, aspirin and clopidogrel -- Urgent surgery early after coronary stenting in a patjent with atrial fibrillation on triple therapy of NOAC (a factor Xa-inhibitor), aspirin and clopidogrel -- Major bleeding early after coronary stenting in a patient with atrial fibrillation on triple therapy of warfarin, aspirin and clopidogrel -- Major bleeding early after coronary stenting in a patient with atrial fibrillation on triple therapy of NOAC (dabigatran), aspirin and clopidogrel.

This book considers paradigmatic clinical cases in order to cast light on key issues relating to elective or emergency stent implantation and the use of oral anticoagulation (OAC) in patients with atrial fibrillation. The topics addressed include the optimal periprocedural antithrombotic treatment (uninterrupted vs interrupted OAC, intraprocedural use of heparin and glycoprotein IIb/IIIa inhibitors, etc.), the most appropriate type of stent (bare metal vs drug eluting vs “bioactive”), the optimal regimen (e.g., triple therapy of OAC, aspirin, and clopidogrel vs the combination of OAC and a single antiplatelet agent), and the most suitable duration of the antithrombotic treatment prescribed at discharge (1 vs 6–12 months). The case-based management recommendations will be of wide practical value in the current health care context, where percutaneous coronary intervention is available even to patients with relevant co-morbidities, such as those warranting long-term OAC, and the indications for OAC are much broader than in the past. The book will appeal especially to clinical and interventional cardiologists, internal medicine specialists, hematologists, and family physicians and will also be of interest to cardiology and internal medicine residents and fellows.